Abiopharma

🔍 Saxonov Serge (Executive)

Company: 10x Genomics, Inc. (TXG)

Report Date: 2026-04-14

Detailed Transactions and Holdings:

• Sold 5,000 shares of Class A Common Stock at $24.5568 per share (Direct)
  Date: 2026-04-14 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,167,273.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-04-14 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 27.00 | Footnotes: F3
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-04-14 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 213,250.00 | Footnotes: F4
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-04-14 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 71,644.00 | Footnotes: F5

Footnotes:

• F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.
• F2: This transaction was executed in multiple trades at prices ranging from $24.49 to $24.70, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
• F3: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
• F4: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
• F5: The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.